On Thursday, Shares of Abbott Laboratories (NYSE:ABT), gained 1.28% to $41.15.
The stock was trading on above-average volume. The stock traded at a volume of 9,812,200 shares at a price gain of 1.30%. The share price is now down -17.17% for the past three months. Latest closing price was -9.35% below its 50-day moving average and -11.93% below its 200-day moving average.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
Shares of CBS Corporation (NYSE:CBS), inclined 3.44% to $43.87, during its last trading session.
CBS Corporation has market worth of $20.63B while 444.41 million shares were outstanding. The company offered net profit margin of 20.20% while its gross profit margin was 40.30%. ROE was recorded as 41.40% while beta factor was 1.94. The stock has shown 3.27% volatility for the week while for the month it is maintained at 2.69%.
CBS Corporation operates as a mass media company worldwide. It operates through four segments: Entertainment, Cable Networks, Publishing, and Local Broadcasting. The Entertainment segment distributes a plan of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and distributes programming, counting series, specials, news, and public affairs; operates online content networks for information and entertainment; and produces, acquires, and distributes theatrical motion pictures.
Finally, Cardiovascular Systems Inc (NASDAQ:CSII), ended its last trade with -18.10% loss, and closed at $13.62.
Cardiovascular Systems, stated preliminary results for its fiscal 2016 first quarter ended September 30, 2015.
The company anticipates fiscal first-quarter revenues of about $43.9 million, an 11 percent improvement from $39.5 million in the first quarter of fiscal 2015, not taking into account $1.9 million from the sale of Asahi guide wires in the preceding year period. The fiscal 2016 first quarter net loss is anticipated to be in the range of $(13.1) million to $(13.9) million, or $(0.41) to $(0.43) per common share, contrast to a net loss of $(8.2) million, or $(0.26) per common share, in the fiscal 2015 first quarter. CSI’s fiscal 2016 first-quarter results are preliminary and may change as the company completes its customary close procedures and independent auditor review.
David L. Martin, CSI’s President and Chief Executive Officer, said, “We continued to make progress on our sales optimization strategy to significantly expand our sales organization, while cross training representatives to sell both peripheral and coronary applications. However, as our recent results suggest, some aspects of the transition have been challenging. After a thorough review, we believe we have taken the right steps to address the immediate challenges and continue to expect the vast majority of the optimization effort to be accomplished by the third quarter of this fiscal year.”
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. It offers peripheral arterial disease products, counting Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Diamondback 360 60cm Peripheral OAS access device, and the 4 Diamondback 360 French 1.25 Peripheral OAS access device products for treating a range of plaque types, such as calcified plaque, in leg arteries both above and below the knee and address many of the limitations associated with existing surgical, catheter, and pharmacological treatment alternatives, in addition to Diamondback 360 Coronary OAS, a catheter-based platform to facilitate stent delivery in patients with coronary artery disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
